KBC Group’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$90K Hold
2,802
﹤0.01% 1385
2025
Q4
$118K Hold
2,802
﹤0.01% 1188
2025
Q3
$96K Hold
2,802
﹤0.01% 1286
2025
Q2
$76K Sell
2,802
-1,070
-28% -$31K ﹤0.01% 1386
2025
Q1
$115K Hold
3,872
﹤0.01% 1404
2024
Q4
$153K Buy
3,872
+1,195
+45% +$45.2K ﹤0.01% 1296
2024
Q3
$91K Buy
2,677
+323
+14% +$9.09K ﹤0.01% 1347
2024
Q2
$51K Buy
2,354
+397
+20% +$8.35K ﹤0.01% 1607
2024
Q1
$43K Hold
1,957
﹤0.01% 1635
2023
Q4
$54K Buy
1,957
+884
+82% +$21.3K ﹤0.01% 1476
2023
Q3
$24K Buy
+1,073
New +$27.6K ﹤0.01% 1856

Other funds holding VCYT

KBC Group's VCYT Position: Q1 2026 in Review

KBC Group held its Veracyte (VCYT) position steady in Q1 2026 at 2,802 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

KBC Group first reported a position in VCYT in Q3 2023 and has held it in 11 quarters since. The position peaked at $153K in Q4 2024. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

  • KBC Group held 2,802 shares of Veracyte worth $90K as of Q1 2026.
  • KBC Group left its Veracyte share count unchanged in Q1 2026.
  • Veracyte made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1385 holding.
  • KBC Group first reported a position in Veracyte in Q3 2023 and has held it in 11 quarters since.
  • KBC Group's Veracyte position peaked at $153K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.